 Entera Bio Ltd. ENTX, a leader in the development of orally delivered large molecule therapeutics, announced receipt of approval from the IRBs at the clinical sites for the amendment to its Phase 2 protocol to include the testing of higher doses of EB613. Given the small sample size of this limited interim BMD data readout, we may see some interesting trends but believe the more relevant data will come from the final analysis of all the patients, including those at the higher doses. 